OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Registration to our newsletter is FREE, Join today by entering your email below!

Tag Archives: aml

Busy Month for BioLine RX Ltd. (NASDAQ: BLRX) Has Biopharmaceutical Development Company on the Radar of Investors

Posted on September 24, 2012 by Editor

After closing last week at 2.32 shares of BioLine RX Ltd. (NASDAQ: BLRX) jumped to a high of 2.85 on Monday with heavy trading volume following news that the biopharmaceutical development company had received from the United States Patent and … Continue reading →

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Gaining Momentum Following Reverse Stock Split

Posted on September 19, 2012 by Editor

Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) have spiked to a high of 5.47 today and while they have slipped back down around the 5.24 level they are considerably higher than the 4.04 at which they opened the day. Along … Continue reading →

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

With Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Affecting Reverse Stock Split Have They Bought Enough Time for Treatment of AML in Elderly?

Posted on August 27, 2012 by Editor

Needing to boost their share price to satisfy the 1.00 minimum bid price requirement for continued listing on the NASDAQ Global Market, Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced a 1-for-7 reverse stock split on Friday and on Monday that split … Continue reading →

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Remains as Far from FDA Approval as Ever Despite Recommendation from DSMB

Posted on October 14, 2011 by Editor

Desperate for some good news Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) finally provided shareholders with something positive on Thursday as they announced that the independent Data Safety Monitoring Board (DSMB) recommended that the company’s Phase 3, randomized, registration-directed study of sapacitabine … Continue reading →

Posted in Articles, NASDAQ, Penny Stocks | Tagged , , , , , , , , , , , , | Leave a comment

Investors Growing Impatient with Sunesis Pharmaceuticals as Vosaroxin Phase III Clinical Trial Still Sitting on Shelf

Posted on December 3, 2010 by Editor

There comes a time when a decision spun as wise discretion becomes a question of ability and while Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) doesn’t necessarily find themselves in that boat just yet there has been growing frustration among shareholders as … Continue reading →

Posted in Articles, NASDAQ | Tagged , , , , , , , , , , , | Leave a comment